Loading
A phase 1/2 trial of Pembrolizumab in cervical cancer, run by Qurient Co., Ltd., active and no longer recruiting.
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05438420 by Qurient Co., Ltd., with 120 participants planned, started 2023-01-12 and due to reach its primary completion in 2027-12-30. Interventions recorded: Q702, Pembrolizumab. Conditions listed: Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer. No results are recorded here; the registry entry is the source.